Investor Information

Letter from Chairman


Thank you for your interest in investing in Parallax (OTC: PRLX). We are committed to maximizing shareholder value and providing a challenging and rewarding environment for our employees. We look forward to speaking with the investment community regularly and invite you to contact investor relations should you require additional information or have questions.



Corporate Governance

We believe that strong corporate governance is essential to our long-term success, and guide practices with customers, partners and shareholders. These guidelines are consistent with those set forth by the Securities and Exchange Commission and the NASDAQ Stock Market. Parallax is committed to respect for the interests of our shareholders and employees, transparency and responsibility in all decision-making, efficient cooperation between our executive team and Board of Directors.


  • Audit Committee Charter

  • Compensation Committee Charter

  • Charter of the Nominating and Corporate Governance Committee

  • EDGAR Filings


Market Information


Point-Of-Care Diagnostic Market Trends

Hundreds of tests once considered too complex for POC are now routinely performed outside the laboratory. It is estimated that the professional global in vitro diagnostic (IVD) testing market was valued at approximately $62 billion in 2015 and that the professional POCT market sub-segment was valued at $12.91 billion in 2015, or the equivalent of 19.4% of the global IVD market.

Glucose testing remains the leading point of care testing global segment. Other rapid cardiac markers are growing rapidly, and will continue to grow at a rate larger than central lab testing, powered by continuing trends for adoption and use of these platforms across disciplines, notably cardiac markers, coagulation and infectious disease.

The demand for Point-of-Care Diagnostic is forecasted to grow approximately 9.3% for the next several years primarily driven by the following key growth drivers:

  1. Increase in Older Population & Chronic Disease

  2. Advances in Technology

  3. Laboratory Staff Shortages

  4. Decentralized Laboratory Testing


Parallax Health Management is an integrated digital healthcare company focused on connected health technology-enabled, integrated care delivery products and services on a proprietary platform, that allows for remote communication, diagnosis, treatment, and monitoring of patients.The Company is pleased to announce today that its wholly-owned subsidiary, Parallax Health Management, Inc. ("PHM"), has contracted to deploy "Fotodigm," its novel patent-pending remote patient monitoring ("RPM") and Telehealth technology that provides its clients with a solution to remote care's two biggest challenges; cost and patient adoption.


Investor Relations



For more information, please feel free to reach out to:


LHA Investor Relations 

Jody Cain, Senior Vice President

LHA Investor Relations: Results that Matter

T: 310.691.7100  | C: 310.490.1832  |  |  LinkedIn


Investor FAQ

On what exchange is Parallax's stock listed? What is the ticker symbol?

Parallax is traded on the OTC under the ticker symbol PRLX.

Who is the Company's Attorney?



The attorney the Company is: Peter Hogan | Buchalter, A Professional Corporation | 1000 Wilshire Boulevard, Suite 1500 | Los Angeles, CA 90017-1730 | Direct Dial: (213) 891-5076 | Cell Phone: (310) 497-2499 | Main Number: (213) 891-0700 | |

Who is the Company's Auditor?

The auditor for the Company is: Mike Goldberg, CPA at Freedman & Goldberg CPAs PC. The address is 31150 Northwestern Hwy, Farmington Hills, MI 48334

Who is the Company's Transfer Agent?



The transfer agent for our common stock is: Action Stock Transfer. The address is 2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121.

What is the company's fiscal year?

Parallax operates on a calendar year from January 1 - December 31.